TM editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Earlier today, Revive Therapeutics (TSXV: RVV)  (RVVTF) announced the initiation of a Phase 2 study examining bucillamine as a treatment for cystinuria. This is an important milestone for the company, as bucillamine is the company’s lead development candidate. Last month, Revive announced an expansion of the company’s focus to include research and discovery of cannabinoid-based therapeutics. The company appointed Dr. Pritesh Kumar as Scientific Advisor for this effort.

Expansion into cannabinoid research is not a big stretch for Revive; the company’s mission statement remains largely unchanged. Revive is still focused on advancing novel treatment options for serious and unmet medical needs, with an eye on repurposing proven safe and effective therapeutic agents for rare and orphan diseases. This is evidenced by the initiation of the Phase 2 bucillamine study noted above. However, cannabinoids also fit the model perfectly, and offer potential as both standalone and adjunct therapy treatments for many of the same unmet medical needs Revive has experience targeting through clinical and preclinical development.

Below is an on bucillamine and the Phase 2 initiation, as well as an introduction to the company’s strategy in expanding the pipeline through cannabinoid research.

Revive’s Mission & Bucillamine Update

Revive Therapeutics’ missions statement is to advance novel treatment options for serious and unmet medical needs. Over the past few years, the company’s focus has been on finding known safe and effective agents approved outside the U.S. and repurposing these medicines for orphan diseases through the U.S. 505(b)(2) approval process. Bucillamine is the company’s leading clinical-stage candidate. The drug is a dithiol derivative of tiopronin for the treatment of cystinuria.

Tiopronin, a monothiol, is sold as Thiola® by Retrophin, Inc. for the treatment of cystinuria. Revive’s clinical hypothesis is that bucillamine should be more effective than Thiola at similar doses, potentially allowing Revive to expand the roughly $250 million U.S. cystinuria market, or equally as effective at substantially lower doses, which would allow for improved safety and tolerability – potentially even a lower cost – resulting in big market share gains for Revive.